Should You Take DHA to Protect Your Memory?

For years, the case for taking DHA to protect memory came from observational studies: people with more DHA in their blood tend to have lower dementia rates. Larger randomized trials often failed to show a benefit, and one explanation was that lower doses might not reach the brain in useful amounts. PreventE4, published in eBioMedicine in 2026, tested that explanation directly. High-dose DHA did get into the spinal fluid, and over two years it still didn't measurably improve memory or thinking or slow brain shrinkage.

A trial designed around the delivery problem

The USC investigators had a specific suspicion. APOE4 is a gene variant that raises Alzheimer's risk, and earlier work in people who already had Alzheimer's suggested that carriers accumulate less DHA in spinal fluid after supplementation. A small pilot by the same group showed that a high dose could raise spinal-fluid DHA. PreventE4 was the larger follow-up, built to give DHA its best chance.

The trial randomized 365 adults aged 55 to 80 without dementia to 2 grams a day of algal DHA or placebo for 24 months. Everyone ate little DHA at the start and had at least one dementia risk factor, and randomization was balanced by APOE4 status. According to the investigators, both groups also took a high-dose B vitamin complex. About half the participants agreed to spinal taps, and whether supplementation raised their spinal-fluid DHA-to-arachidonic-acid ratio at six months was the trial's primary question.

The delivery result is solid. In the blood, the omega-3 index more than doubled, from about 5% to 11%. Spinal fluid is still a stand-in, though. More DHA in the fluid around the brain doesn't show that anything changed inside neurons.

Higher levels, no memory benefit

Over two years, DHA didn't separate from placebo on the cognitive measures tested. APOE4 carriers tended to gain less from repeat testing than non-carriers did, which is consistent with their higher risk, and DHA didn't change that pattern.

This result is less certain than the delivery result. Cognition was exploratory and MRI outcomes were secondary, and 38% of participants dropped out, mostly because of COVID-19. A smaller benefit could go undetected in a trial like this. Still, the finding fits what came before it. MAPT, which followed 1,680 older adults, mostly with memory complaints, for three years, found no significant effect of omega-3 supplements on cognitive decline, and an 18-month Australian trial of DHA-rich fish oil in cognitively healthy older adults also came up empty.

The more encouraging signals come from people who already have mild cognitive impairment. Some trials in that group, including one that gave 2 grams of DHA a day for a year, reported better cognitive scores. A trial published in August 2026 reported gains with DHA, and broader gains with DHA plus vitamin D3, though it ran at a single center and was registered after the fact. Those studies looked at a different population, one whose memory had already started to slip. They don't show that DHA prevents dementia in someone whose memory is still normal.

Two years may also be too short. The investigators point out that the silent early stage of Alzheimer's unfolds over many years. Longer trials are worth running for that reason. So far, no randomized trial has shown that DHA reduces the number of people who develop dementia.

Where your effort has better support

The most useful prevention trial in this evidence tested a whole lifestyle program. In FINGER, a randomized trial of 1,260 older Finnish adults at elevated risk, a structured two-year lifestyle intervention improved cognitive performance, and a later analysis found that APOE4 carriers benefited too. If you know you carry APOE4, that matters: the variant raises your risk, but FINGER suggests your thinking can still respond to what you change. FINGER bundled several changes together, so it can't tell you which piece mattered most, and it was never compared head to head with DHA.

The World Health Organization's dementia risk-reduction guidelines, updated in July 2026, point the same way. They recommend against omega-3 supplements for preventing cognitive decline or dementia in people without a diagnosed deficiency. The priorities that run through this evidence are physical activity, blood pressure control, diabetes control and a healthy eating pattern. Blood pressure and blood sugar are both things you can measure yourself and track over time, which gives you something concrete to work on.

If you already take DHA, PreventE4 doesn't raise a safety alarm. Overall adverse-event rates were similar in the two groups over two years, though a trial this size can't rule out rare harms or say how other omega-3 formulations compare. If a clinician prescribed omega-3 for triglycerides or another condition, that decision rests on different evidence and should be weighed on its own terms.

Adding DHA to a prevention plan would make sense if a larger, longer trial with good retention showed meaningfully better memory scores or fewer dementia diagnoses. Any advantage claimed for APOE4 carriers or people who eat little DHA would need to be specified before the trial started and then replicated by another group. PreventE4 has now shown that supplementation raises DHA in blood and spinal fluid, and a higher level on its own can't settle whether memory is being protected.